Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

<p>Supp Tables</p>

Na minha lista:

Detalhes bibliográficos
Autor principal:	Renumathy Dhanasekaran (14962092) (author)
Outros Autores:	Aida S. Hansen (14962095) (author), Jangho Park (14962098) (author), Lea Lemaitre (14962101) (author), Ian Lai (14962104) (author), Nia Adeniji (14962107) (author), Sibu Kuruvilla (14962110) (author), Akanksha Suresh (14962113) (author), Josephine Zhang (14962116) (author), Varsha Swamy (14962119) (author), Dean W. Felsher (14962122) (author)
Publicado em:	2025
Assuntos:	Cancer Cancer Biology Immuno-oncology Immunology Immune responses to cancer Tumor-associated macrophages Immunotherapy Checkpoint blockade Combination immunotherapy Oncogenes & Tumor Suppressors Oncogenes
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
por: Hansol Lee (15054787)
Publicado em: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
por: Hansol Lee (15054787)
Publicado em: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
por: Hansol Lee (15054787)
Publicado em: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
por: Hansol Lee (15054787)
Publicado em: (2025)

Figure S.1 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado em: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado em: (2025)

Figure S.3 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado em: (2025)

Figure S.4 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado em: (2025)

Figure S.5 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado em: (2025)

Figure S.6 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado em: (2025)

Figure S.7 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado em: (2025)

Figure S.8 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado em: (2025)

Supplementary Figure 1 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
por: Francisco Exposito (16721403)
Publicado em: (2025)

Supplementary Figure 2 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
por: Francisco Exposito (16721403)
Publicado em: (2025)

Supplementary Figure 3 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
por: Francisco Exposito (16721403)
Publicado em: (2025)

Supplementary Figure 4 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
por: Francisco Exposito (16721403)
Publicado em: (2025)

Supplementary Figure 5 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
por: Francisco Exposito (16721403)
Publicado em: (2025)

Figure S1 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
por: Xiaodong Shu (16721586)
Publicado em: (2025)

Figure S2 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
por: Xiaodong Shu (16721586)
Publicado em: (2025)

Figure S3 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
por: Xiaodong Shu (16721586)
Publicado em: (2025)

Figure S4 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
por: Xiaodong Shu (16721586)
Publicado em: (2025)

Figure S5 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
por: Xiaodong Shu (16721586)
Publicado em: (2025)

Figure S6 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
por: Xiaodong Shu (16721586)
Publicado em: (2025)

Figure S7 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
por: Xiaodong Shu (16721586)
Publicado em: (2025)

Table S1-S9 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
por: Xiaodong Shu (16721586)
Publicado em: (2025)

Supp. Figure 1 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
por: Renzo Perales-Linares (17314863)
Publicado em: (2025)

Supp. Figure 2 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
por: Renzo Perales-Linares (17314863)
Publicado em: (2025)

Supp. Figure 3 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
por: Renzo Perales-Linares (17314863)
Publicado em: (2025)

Supp. Figure 4 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
por: Renzo Perales-Linares (17314863)
Publicado em: (2025)

Supp. Figure 5 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
por: Renzo Perales-Linares (17314863)
Publicado em: (2025)

Supp. Figure 6 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
por: Renzo Perales-Linares (17314863)
Publicado em: (2025)

Supplementary Table S3 from The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma
por: Shima Nakanishi (16336496)
Publicado em: (2025)

Supplementary Table S4 from The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma
por: Shima Nakanishi (16336496)
Publicado em: (2025)

Supplementary Table 1 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
por: Duygu Kuzuoglu-Ozturk (14960213)
Publicado em: (2025)

Supplementary Table 2 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
por: Duygu Kuzuoglu-Ozturk (14960213)
Publicado em: (2025)

Supplementary Table 3 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
por: Duygu Kuzuoglu-Ozturk (14960213)
Publicado em: (2025)

Supplementary Table 1 - Gene Expression from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
por: Renzo Perales-Linares (17314863)
Publicado em: (2025)

Supplementary Table S1-19 from Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations
por: Yuxi Liu (15293121)
Publicado em: (2025)

Table 1_The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.docx
por: Soyoung Kim (117362)
Publicado em: (2025)

Supplementary Tables from The IGF2BP3–COPS7B Axis Facilitates mRNA Translation to Drive Colorectal Cancer Progression
por: Jing Tang (17314958)
Publicado em: (2025)

Cannot write session to /tmp/vufind_sessions/sess_qvn4e27kugep7sit044jvitqcp